KR101407131B1 - 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템 - Google Patents

경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템 Download PDF

Info

Publication number
KR101407131B1
KR101407131B1 KR1020047020117A KR20047020117A KR101407131B1 KR 101407131 B1 KR101407131 B1 KR 101407131B1 KR 1020047020117 A KR1020047020117 A KR 1020047020117A KR 20047020117 A KR20047020117 A KR 20047020117A KR 101407131 B1 KR101407131 B1 KR 101407131B1
Authority
KR
South Korea
Prior art keywords
substrate
tdd
delete delete
opioid
adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047020117A
Other languages
English (en)
Korean (ko)
Other versions
KR20050020977A (ko
Inventor
칼 제이. 베이커
아이홀 쉬브척
Original Assignee
유로-셀티크 소시에떼 아노뉨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로-셀티크 소시에떼 아노뉨 filed Critical 유로-셀티크 소시에떼 아노뉨
Publication of KR20050020977A publication Critical patent/KR20050020977A/ko
Application granted granted Critical
Publication of KR101407131B1 publication Critical patent/KR101407131B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
    • B09B3/70—Chemical treatment, e.g. pH adjustment or oxidation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Processing Of Solid Wastes (AREA)
KR1020047020117A 2002-06-10 2003-06-10 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템 Expired - Fee Related KR101407131B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38780002P 2002-06-10 2002-06-10
US60/387,800 2002-06-10
PCT/US2003/018256 WO2003103673A1 (en) 2002-06-10 2003-06-10 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117022754A Division KR20110120358A (ko) 2002-06-10 2003-06-10 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템

Publications (2)

Publication Number Publication Date
KR20050020977A KR20050020977A (ko) 2005-03-04
KR101407131B1 true KR101407131B1 (ko) 2014-06-19

Family

ID=29736367

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117022754A Ceased KR20110120358A (ko) 2002-06-10 2003-06-10 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
KR1020047020117A Expired - Fee Related KR101407131B1 (ko) 2002-06-10 2003-06-10 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020117022754A Ceased KR20110120358A (ko) 2002-06-10 2003-06-10 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템

Country Status (22)

Country Link
US (2) US20040033255A1 (enExample)
EP (4) EP1837023A1 (enExample)
JP (3) JP4949625B2 (enExample)
KR (2) KR20110120358A (enExample)
CN (2) CN101455649B (enExample)
AT (1) ATE355061T1 (enExample)
AU (2) AU2003251482A1 (enExample)
CA (1) CA2488915C (enExample)
CY (1) CY1107630T1 (enExample)
DE (1) DE60312160T2 (enExample)
DK (1) DK1513532T3 (enExample)
EA (1) EA007240B1 (enExample)
ES (1) ES2283812T3 (enExample)
IL (1) IL165517A0 (enExample)
MX (1) MXPA04012333A (enExample)
NO (1) NO334455B1 (enExample)
NZ (1) NZ537180A (enExample)
PT (1) PT1513532E (enExample)
SI (1) SI1513532T1 (enExample)
UA (1) UA82194C2 (enExample)
WO (1) WO2003103673A1 (enExample)
ZA (1) ZA200409495B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
NZ542969A (en) * 2003-04-30 2009-09-25 Purdue Pharma Lp Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
EP2074989B1 (en) * 2004-02-23 2013-11-20 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US20060045897A1 (en) * 2004-08-27 2006-03-02 Aso Corporation Occlusive articles for wart treatment
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
WO2006069008A1 (en) * 2004-12-22 2006-06-29 Vesta Medical, Llc Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
CN101330903B (zh) * 2005-12-13 2015-07-08 生物递送科学国际公司 防滥用的经黏膜给药装置
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
US20080226702A1 (en) * 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
MX2010010512A (es) * 2008-03-26 2010-11-09 Alltranz Inc Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso.
DE202008004785U1 (de) * 2008-04-04 2009-08-13 Grünenthal GmbH Entsorgungsvorrichtung
US8329210B2 (en) * 2008-09-23 2012-12-11 Pharmapatch, Llc Twin transdermal drug delivery patch
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US8507182B2 (en) * 2009-06-09 2013-08-13 Eastman Kodak Company Method of providing lithographic printing plates
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
DK2552245T3 (en) 2010-03-26 2019-01-07 Philip Morris Products Sa INHIBITION OF SENSORY IRRITATION UNDER CONSUMPTION OF NON-SMOKABLE TOBACCO PRODUCTS
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
ES2660116T3 (es) 2011-08-18 2018-03-20 Biodelivery Sciences International, Inc. Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
US8979724B2 (en) 2011-09-30 2015-03-17 Teikoku Pharma Usa, Inc. General medication disposal system
US8790583B2 (en) 2011-09-30 2014-07-29 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
JP6980533B2 (ja) 2015-02-19 2021-12-15 キャンデサント・バイオメディカル・インコーポレイテッドCandesant Biomedical, Inc. 熱を発生させるための医療用デバイスおよびこれを用いた治療方法
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
US20170273974A1 (en) 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
ES2957234T3 (es) 2016-03-24 2024-01-15 Medrx Co Ltd Preparación de parche con características de prevención del uso incorrecto de sustancias
US10532385B2 (en) * 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019059377A1 (ja) 2017-09-22 2019-03-28 株式会社 メドレックス 再貼付不可能な貼付剤
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
AU2020402859A1 (en) * 2019-12-10 2022-07-07 Candesant Biomedical, Inc. Methods and systems for disposing alkali metal patches
EP4378432A3 (en) 2019-12-10 2024-07-31 Candesant Biomedical, Inc. Medical device for generating heat
CN119588727B (zh) * 2024-12-06 2025-09-26 奕瑞新材料科技（太仓）有限公司 一种碘化铯闪烁屏用激活剂提纯系统、提纯方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
WO2000041683A2 (de) * 1999-01-14 2000-07-20 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit einer selbstklebenden matrix, enthaltend organische säure-additionssalze von alkaloiden des morphin- bzw. morphinantyps

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527864A (en) 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3540580A (en) * 1967-07-03 1970-11-17 Borden Inc Heat-seal adhesive and package
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3903256A (en) 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4046886A (en) 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4130667A (en) 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4335115A (en) 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4166058A (en) * 1978-08-11 1979-08-28 The Goodyear Tire & Rubber Company Heat sensitive primer exhibiting color change and containing a resin blend, elemental sulfur, and a dye
US4326566A (en) 1979-09-11 1982-04-27 N. V. Weefautomaten Picanol Color selector
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4248748A (en) * 1980-02-04 1981-02-03 Minnesota Mining And Manufacturing Company Heat-activated adhesive
DE3047635A1 (de) * 1980-12-17 1982-07-22 Hilti AG, 9494 Schaan Klebeverfahren mittels schmelzklebstoff sowie mittel zur durchfuehrung des verfahrens
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4560553A (en) 1981-07-07 1985-12-24 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4510621A (en) * 1983-06-30 1985-04-09 Arvey Corporation Self-sealing pouch for forming adhesive-to-adhesive seal
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
JPS61103840A (ja) 1984-10-26 1986-05-22 Nitto Electric Ind Co Ltd 外皮投与用組成物
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5066648A (en) 1985-11-29 1991-11-19 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US4973968A (en) 1986-03-07 1990-11-27 Plessey Overseas Limited Radar system for determining first time around targets from multiple time around targets
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4940586A (en) 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5225473A (en) * 1987-11-25 1993-07-06 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesives
GB8811669D0 (en) * 1988-05-17 1988-06-22 Alcan Int Ltd Colour-changeable adhesive
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
US5378730A (en) 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
JP3196851B2 (ja) * 1991-04-01 2001-08-06 積水化学工業株式会社 医療用貼付剤
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5308887A (en) * 1991-05-23 1994-05-03 Minnesota Mining & Manufacturing Company Pressure-sensitive adhesives
US5981666A (en) * 1991-07-12 1999-11-09 Adhesives Research, Inc. Method for the production of a high performance pressure sensitive adhesive
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5238933A (en) 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
CA2097163C (en) 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US6162456A (en) 1992-09-24 2000-12-19 Ortho-Mcneil Pharmaceutical, Inc. Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers
JPH0710742Y2 (ja) * 1993-02-05 1995-03-15 日本臓器製薬株式会社 救急絆創膏
EP0813865B1 (de) * 1993-04-20 2001-09-19 Hexal Ag Wirkstoffpflaster
US5520385A (en) * 1993-07-30 1996-05-28 Composite Development Corporation Article assembled with thermoreponsive material and method
KR960704578A (ko) 1993-09-29 1996-10-09 에드워드 엘. 만델 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
US5470529A (en) * 1994-03-08 1995-11-28 Sumitomo Metal Industries, Ltd. High tensile strength steel sheet having improved formability
US5420106A (en) 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
AU4990797A (en) 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
WO1998018416A1 (en) 1996-10-30 1998-05-07 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5804215A (en) * 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US6017983A (en) * 1998-01-29 2000-01-25 Alpha Metals, Inc. Color indicator for completion of polymerization for thermosets
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
ES2587358T3 (es) * 2001-04-23 2016-10-24 Euro-Celtique S.A. Sistema de desecho para forma farmacéutica transdérmica
DE60230138D1 (de) * 2001-05-01 2009-01-15 Euro Celtique Sa Vor missbrauch geschützte opioid-haltige transdermale systeme
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
WO2000041683A2 (de) * 1999-01-14 2000-07-20 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit einer selbstklebenden matrix, enthaltend organische säure-additionssalze von alkaloiden des morphin- bzw. morphinantyps

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
논문 Journal of Controlled Release (Vol.34. 1995) *
논문 The Annals of Pharmacotherapy (Vol.29, 1995) *

Also Published As

Publication number Publication date
ES2283812T3 (es) 2007-11-01
US20080274168A1 (en) 2008-11-06
JP2005538058A (ja) 2005-12-15
AU2009217420A1 (en) 2009-10-15
CN100525767C (zh) 2009-08-12
US20040033255A1 (en) 2004-02-19
UA82194C2 (uk) 2008-03-25
JP2014088422A (ja) 2014-05-15
IL165517A0 (en) 2006-01-15
AU2003251482A1 (en) 2003-12-22
NO20050126L (no) 2005-01-10
EP2266565A1 (en) 2010-12-29
ATE355061T1 (de) 2006-03-15
JP2011016802A (ja) 2011-01-27
DK1513532T3 (da) 2007-07-02
CN101455649A (zh) 2009-06-17
CY1107630T1 (el) 2013-04-18
DE60312160D1 (de) 2007-04-12
NO334455B1 (no) 2014-03-10
KR20050020977A (ko) 2005-03-04
EA200401564A1 (ru) 2005-08-25
JP5898242B2 (ja) 2016-04-06
MXPA04012333A (es) 2005-02-25
EP1513532A1 (en) 2005-03-16
CA2488915C (en) 2011-10-04
CN101455649B (zh) 2014-02-26
CA2488915A1 (en) 2003-12-18
NZ537180A (en) 2008-03-28
EA007240B1 (ru) 2006-08-25
EP1837023A1 (en) 2007-09-26
SI1513532T1 (sl) 2007-08-31
EP1513532B1 (en) 2007-02-28
CN1658878A (zh) 2005-08-24
EP2298302A1 (en) 2011-03-23
KR20110120358A (ko) 2011-11-03
JP5507367B2 (ja) 2014-05-28
WO2003103673A1 (en) 2003-12-18
PT1513532E (pt) 2007-05-31
AU2009217420B2 (en) 2013-06-13
JP4949625B2 (ja) 2012-06-13
DE60312160T2 (de) 2007-10-31
ZA200409495B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
KR101407131B1 (ko) 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
EP1530469B1 (en) Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist
EP3064199B1 (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20080020028A1 (en) Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
AU2013204813B2 (en) Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20130114

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2004 7020117

Appeal request date: 20110928

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2011101007021

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180601

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190606

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190606